Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

BACKGROUND: The magnitude and rapidity of the tumor response to androgen deprivation is known to predict the durability of the therapy. We have investigated the predictive value of categorizing patients by the half-life of PSA under neoadjuvant androgen deprivation therapy in patients with biochemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yong Jin, Jang, Won Sik, Kwon, Jong Kyou, Yoon, Cheol Yong, Lee, Joo Yong, Ham, Won Sik, Choi, Young Deuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701379/
https://www.ncbi.nlm.nih.gov/pubmed/29169347
http://dx.doi.org/10.1186/s12885-017-3775-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701379/
https://www.ncbi.nlm.nih.gov/pubmed/29169347
http://dx.doi.org/10.1186/s12885-017-3775-6

Ejemplares similares